<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431584</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 046-17</org_study_id>
    <nct_id>NCT03431584</nct_id>
  </id_info>
  <brief_title>Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.</brief_title>
  <acronym>RHIZ'ART</acronym>
  <official_title>Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rhizarthrosis, or the degenerative osteoarthritis of the trapezo-metacarpal joint, is a
      frequent degenerative osteoarthritis.

      The treatment associates not pharmacological measures, such as resting relative of the joint,
      the orthosis of rest, glazing and pharmacological measures such analgesic, anti-inflammatory
      not steroidal per bones or premises, even infiltrations cortisone or by hyaluronic acid.

      No study has, for the moment, tested the interest of the combination of cortisone and
      hyaluronic acid in rhizarthrosis. In view of the current publications, we propose to carry
      out a study on two arms, with corticosteroids in reference arm; the experimental arm is the
      combination of hyaluronic acid and cortisone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analogical visual scale of pain (VAS)</measure>
    <time_frame>3 month post infiltration</time_frame>
    <description>Analogical visual scale of pain (VAS) To 0mm (no pain) form 100mm (maximum pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of pain to activity at protocol follow-up visits</measure>
    <time_frame>1 month, 6 month, and 12 month post infiltration</time_frame>
    <description>Analogical visual scale of pain (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of pain at rest at protocol follow-up visits</measure>
    <time_frame>Base-line,1 month, 3month, 6 month, and 12 month post infiltration</time_frame>
    <description>Analogical visual scale of pain (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pain between M0 and M3, by weekly collection on a patient book</measure>
    <time_frame>3 month post infiltration</time_frame>
    <description>Analogical visual scale of pain (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the fhand unction with Cochin Hand Function Scale</measure>
    <time_frame>1 month, 6 month, and 12 month post infiltration</time_frame>
    <description>Cochin Hand Function Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the grip and opposition force</measure>
    <time_frame>1 month, 3 month, 6 month, and 12 month post infiltration</time_frame>
    <description>dynamometer mesures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound appearance of lesions</measure>
    <time_frame>Baseline and 3 month post infiltration</time_frame>
    <description>ultrasound b-mode and Doppler - gradation of OMERACT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of infiltration pain</measure>
    <time_frame>the day of infiltration</time_frame>
    <description>Analogical visual scale of pain (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's feelings about the evolution of his pain</measure>
    <time_frame>3 month post infiltration</time_frame>
    <description>Verbal Scale of global evolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for new infiltrations</measure>
    <time_frame>over the 12 months of follow-up</time_frame>
    <description>Number of corticosteroid infiltrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of analgesics and NSAIDs</measure>
    <time_frame>over the 12 months of follow-up</time_frame>
    <description>Use of analgesics and NSAIDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgical procedure</measure>
    <time_frame>over the 12 months of follow-up</time_frame>
    <description>Number of patient requiring a surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days off work</measure>
    <time_frame>over the 12 months of follow-up</time_frame>
    <description>Number of days off work</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rhizarthrosis</condition>
  <arm_group>
    <arm_group_label>Infiltration of corticosteroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Infiltration of corticosteroids and hyaluronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infiltration of corticosteroids</intervention_name>
    <description>infiltration of corticosteroids</description>
    <arm_group_label>Infiltration of corticosteroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infiltration of corticosteroids and hyaluronic acid</intervention_name>
    <description>infiltration of corticosteroids and hyaluronic acid</description>
    <arm_group_label>Infiltration of corticosteroids and hyaluronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, ≥ 40 years

          -  Pain located at the root of the thumb (near the wrist) and awakened by direct pressure
             and movement

          -  Pain resistant to well-conducted medical treatment, with analgesics, NSAIDs, icing
             with pain (analog visual scale) ≥ 4 for more than 3 months

          -  Radiological findings (kapandji face + profile incidence) typical of rhizarthrosis,
             stage II or III of Eaton and Litter, with at least 2 of the following 5 radiological
             elements observed on the trapeziometacarpal joint:

               -  marginal osteophyte

               -  pinching of the joint space

               -  sclerosis of the subchondral space

               -  subchondral kyst

               -  absence of osteopenia

          -  Patient with the ability to understand the protocol and signed informed consent

          -  Patient receiving social security

        Exclusion Criteria:

          -  Known allergy to any of the products (corticosteroids or hyaluronic acid) including
             its excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl
             alcohol)

          -  Change of analgesic treatment within 4 weeks before inclusion.

          -  Patients with symptomatic bilateral rhizarthrosis

          -  Scaphoid-trapezial arthrosis

          -  Local or general infection

          -  Severe coagulation disorders, ongoing anticoagulant therapy

          -  severe and / or uncontrolled hypertension

          -  Earlier local surgery

          -  Associated inflammatory rheumatism

          -  Tendinopathy of De Quervain, thumb to jump associated

          -  Infiltrations earlier than 6 months

          -  Diabetes imbalanced

          -  Live vaccines

          -  Severe water and / or sodium retention (hypernatremia), particularly in cases of heart
             failure, decompensated liver failure (edema and ascites failure)

          -  Pregnant or lactating women

          -  Immunocompromised or hemodialysis patients

          -  Patients under guardianship, trusteeship, or deprived of liberty

          -  Patients participating in another clinical research protocol involving a drug or
             medical device

          -  Patients unable to follow the protocol, according to the judgment of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agnes Dorion</last_name>
    <phone>0251446380</phone>
    <phone_ext>+33</phone_ext>
    <email>agnes.dorion@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grégoire CORMIER, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amélie DENIS, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benoit LE GOFF, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

